ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $1,167,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRYGet Free Report) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the completion of the transaction, the insider now directly owns 1,098,499 shares in the company, valued at $12,819,483.33. This trade represents a 8.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

  • On Tuesday, December 10th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00.
  • On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Trading Down 1.2 %

NASDAQ:SPRY opened at $11.18 on Friday. The firm has a market capitalization of $1.09 billion, a PE ratio of -21.92 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 1 year low of $5.02 and a 1 year high of $18.51. The firm’s fifty day simple moving average is $14.37 and its 200 day simple moving average is $12.43.

Analysts Set New Price Targets

SPRY has been the topic of several recent research reports. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $24.00.

Get Our Latest Research Report on ARS Pharmaceuticals

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SPRY. Barclays PLC lifted its position in shares of ARS Pharmaceuticals by 189.7% during the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock worth $1,618,000 after purchasing an additional 73,127 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of ARS Pharmaceuticals by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock worth $17,909,000 after buying an additional 38,927 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of ARS Pharmaceuticals in the third quarter valued at approximately $250,000. Wellington Management Group LLP grew its stake in shares of ARS Pharmaceuticals by 38.9% in the third quarter. Wellington Management Group LLP now owns 162,335 shares of the company’s stock worth $2,354,000 after acquiring an additional 45,452 shares during the last quarter. Finally, Wexford Capital LP bought a new position in ARS Pharmaceuticals during the third quarter worth $3,601,000. 68.16% of the stock is owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Recommended Stories

Insider Buying and Selling by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.